LINC00511

Summary

LINC00511 (long intergenic non-protein coding RNA 511, HGNC:43564) is a long non-coding RNA gene on chromosome 17q24.3.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43564
Approved symbol	LINC00511
Name	long intergenic non-protein coding RNA 511
Location	17q24.3
Locus type	RNA, long non-coding
Status	Approved
Aliases	onco-lncRNA-12
Ensembl gene	ENSG00000227036
Ensembl biotype	lncRNA
Entrez	400619
RNAcentral	URS00001710A5 — lncRNA, 2265 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 108 — 106 lncRNA, 2 retained_intron

ENST00000453722, ENST00000457958, ENST00000577773, ENST00000577828, ENST00000578206, ENST00000579631, ENST00000580175, ENST00000580199, ENST00000580500, ENST00000580861, ENST00000580948, ENST00000581183, ENST00000581549, ENST00000581801, ENST00000582712, ENST00000583460, ENST00000584749, ENST00000647593, ENST00000647611, ENST00000647652, ENST00000647706, ENST00000647735, ENST00000647850, ENST00000647871, ENST00000647953, ENST00000648054, ENST00000648069, ENST00000648088, ENST00000648104, ENST00000648176, ENST00000648203, ENST00000648220, ENST00000648248, ENST00000648297, ENST00000648401, ENST00000648403, ENST00000648411, ENST00000648428, ENST00000648500, ENST00000648520, ENST00000648522, ENST00000648559, ENST00000648623, ENST00000648631, ENST00000648667, ENST00000648672, ENST00000648840, ENST00000648907, ENST00000648952, ENST00000648954, ENST00000649013, ENST00000649074, ENST00000649172, ENST00000649197, ENST00000649250, ENST00000649269, ENST00000649311, ENST00000649330, ENST00000649332, ENST00000649343, ENST00000649350, ENST00000649366, ENST00000649407, ENST00000649433, ENST00000649440, ENST00000649489, ENST00000649532, ENST00000649553, ENST00000649595, ENST00000649597, ENST00000649614, ENST00000649647, ENST00000649733, ENST00000649793, ENST00000649833, ENST00000649881, ENST00000649936, ENST00000650016, ENST00000650033, ENST00000650051, ENST00000650083, ENST00000650121, ENST00000650131, ENST00000650161, ENST00000650180, ENST00000650191, ENST00000650194, ENST00000650211, ENST00000650212, ENST00000650227, ENST00000650289, ENST00000650313, ENST00000650357, ENST00000650371, ENST00000650419, ENST00000650423, ENST00000650476, ENST00000650482, ENST00000650483, ENST00000650499, ENST00000650510, ENST00000650550, ENST00000650554, ENST00000650570, ENST00000650600, ENST00000650602, ENST00000701652, ENST00000715416

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000453722 — 5 exons

Exon	Start	End
ENSE00001629418	72592203	72592804
ENSE00001711342	72384302	72385137
ENSE00001790402	72428236	72428298
ENSE00002733117	72401304	72401421
ENSE00004026734	72431128	72431224

Expression profiles

Bgee: expression breadth ubiquitous, 213 present calls, max score 95.80.

FANTOM5 (CAGE): breadth broad, TPM avg 0.5184 / max 17.9571, expressed in 257 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
167862	2.1955	783
167856	0.2279	123
167861	0.1555	65
167858	0.0418	18
167857	0.0362	12
167863	0.0295	11
167855	0.0275	3
167854	0.0194	3

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	95.80	gold quality
nasal cavity epithelium	UBERON:0005384	94.00	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.98	gold quality
sural nerve	UBERON:0015488	93.82	gold quality
ileal mucosa	UBERON:0000331	93.16	gold quality
islet of Langerhans	UBERON:0000006	92.44	gold quality
cartilage tissue	UBERON:0002418	91.88	gold quality
epithelial cell of pancreas	CL:0000083	91.35	gold quality
colonic epithelium	UBERON:0000397	90.64	gold quality
palpebral conjunctiva	UBERON:0001812	90.09	gold quality
mucosa of transverse colon	UBERON:0004991	90.07	gold quality
lower esophagus mucosa	UBERON:0035834	89.04	gold quality
nasal cavity mucosa	UBERON:0001826	87.75	gold quality
ventricular zone	UBERON:0003053	87.20	gold quality
bronchial epithelial cell	CL:0002328	86.42	gold quality
rectum	UBERON:0001052	86.11	gold quality
skin of leg	UBERON:0001511	86.08	gold quality
bronchus	UBERON:0002185	86.03	gold quality
skin of abdomen	UBERON:0001416	85.42	gold quality
zone of skin	UBERON:0000014	84.71	gold quality
esophagus mucosa	UBERON:0002469	84.67	gold quality
epithelium of nasopharynx	UBERON:0001951	84.63	gold quality
tibia	UBERON:0000979	84.11	gold quality
upper arm skin	UBERON:0004263	83.18	gold quality
pancreas	UBERON:0001264	82.97	gold quality
pharyngeal mucosa	UBERON:0000355	82.15	gold quality
tibial nerve	UBERON:0001323	82.05	gold quality
colonic mucosa	UBERON:0000317	81.67	gold quality
caudate nucleus	UBERON:0001873	81.63	gold quality
trachea	UBERON:0003126	81.63	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	68.09
E-HCAD-25	yes	23.03
E-ANND-3	yes	16.86

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 38)

• Study validated the role of 2 uncharacterized lncRNAs, onco-lncRNA-3 and onco-lncRNA-12, and a previously reported lncRNA, CCAT1, in S-phase cell cycle across cancer types. (PMID:25864709)
• linc00511 could up-regulate VEGFA via its competing endogenous RNA (ceRNA) activity on hsa-miR-29b-3p. (PMID:28984028)
• LINC00511 served as a competing endogenous RNA (ceRNA) through sponging miR-765 and ultimately modulated the derepression of laminin subunit gamma 2 (LAMC2). (PMID:29315846)
• This study showed that linc00511 was highly expressed in bladder cancer tissues and cells. Linc00511 knockdown could cause the cell proliferation suppression and cell cycle arrest, which were mediated by p18, p21, CDK4, cyclin D1 and phosphorylation Rb. (PMID:30042171)
• Data concludes that LINC00511/miR-185-3p/E2F1/Nanog axis facilitates the breast cancer stemness and tumorigenesis, providing a vital insight for them. (PMID:30482236)
• Up-regulation of LINC00511 is associated with glioma progression. (PMID:30973678)
• Increased long noncoding RNA LINC00511 is correlated with poor prognosis and contributes to cell proliferation and metastasis by modulating miR-424 in hepatocellular carcinoma. (PMID:31081082)
• LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel. (PMID:31180057)
• mechanistic investigations demonstrated that ER-negative-associated LINC00511 interacted with enhancer of zeste homologue 2 (EZH2, the catalytic subunit of polycomb repressive complex 2, PRC2) and recruited PRC2 to mediate histone methylation, contributing to the repression of CDKN1B in the nucleus. (PMID:31395854)
• LINC00511 is associated with the malignant status and promotes cell proliferation and motility in cervical cancer. (PMID:31434692)
• LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop. (PMID:31856394)
• Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo. (PMID:31893577)
• LINC00511 promotes proliferation and invasion by sponging miR-515-5p in gastric cancer. (PMID:32042282)
• Knockdown of Linc00511 inhibits TGF-beta-induced cell migration and invasion by suppressing epithelial-mesenchymal transition and down-regulating MMPs expression. (PMID:32092827)
• LINC00511 can promote the proliferation, migration and invasion of esophageal cancer cells through regulating microRNA-150-5p. (PMID:32196597)
• LINC00511 exacerbated T-cell acute lymphoblastic leukemia via miR-195-5p/LRRK1 axis. (PMID:32242897)
• Long noncoding RNA LINC00511 promoted cell proliferation and invasion via regulating miR-124-3p/EZH2 pathway in gastric cancer. (PMID:32373959)
• Long noncoding RNA LINC00511 regulates the proliferation, apoptosis, invasion and autophagy of trophoblast cells to mediate pre-eclampsia progression through modulating the miR-31-5p/homeobox protein A7 axis. (PMID:32558037)
• LINC00511 as a prognostic biomarker for human cancers: a systematic review and meta-analysis. (PMID:32698787)
• Long non-coding RNA LINC00511/miR-150/MMP13 axis promotes breast cancer proliferation, migration and invasion. (PMID:33031905)
• Clinicopathological and Prognostic Significance of Long Non-Coding RNA LINC00511 in Solid Tumors. (PMID:33739039)
• LINC00511 drives invasive behavior in hepatocellular carcinoma by regulating exosome secretion and invadopodia formation. (PMID:34088337)
• Long non-coding RNA LINC00511 regulates the expression of microRNA-625-5p and activates signal transducers and activators of transcription 3 (STAT3) to accelerate the progression of gastric cancer. (PMID:34224294)
• LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/beta-catenin signaling. (PMID:34328678)
• LINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathway. (PMID:34427967)
• Upregulation of VDR-associated lncRNAs in Schizophrenia. (PMID:34499334)
• LINC00511 Knockdown Suppresses Resistance to Cisplatin in Lung Adenocarcinoma by Interacting with miR-182-3p and BIRC5. (PMID:34595724)
• Knockdown of LINC00511 decreased cisplatin resistance in non-small cell lung cancer by elevating miR-625 level to suppress the expression of leucine rich repeat containing eight volume-regulated anion channel subunit E. (PMID:35363093)
• LINC00511 enhances LUAD malignancy by upregulating GCNT3 via miR-195-5p. (PMID:35399076)
• LncRNA LINC00511 promotes COL1A1-mediated proliferation and metastasis by sponging miR-126-5p/miR-218-5p in lung adenocarcinoma. (PMID:35842617)
• IncRNA Linc00511 Upregulation Elevates TGFBR1 and Participates in the Postoperative Distant Recurrence of Non-Small-Cell Lung Cancer by Targeting miR-98-5p. (PMID:35993940)
• LINC00511 promotes cervical cancer progression by regulating the miR-497-5p/MAPK1 axis. (PMID:36103025)
• Extracellular vesicle-derived LINC00511 promotes glycolysis and mitochondrial oxidative phosphorylation of pancreatic cancer through macrophage polarization by microRNA-193a-3p-dependent regulation of plasminogen activator urokinase. (PMID:36476048)
• Linc00511 Knockdown Inhibited TGF-beta1-Induced Epithelial-Mesenchymal Transition of Bronchial Epithelial Cells by Targeting miR-16-5p/Smad3. (PMID:36594176)
• Knockdown of LINC00511 enhances radiosensitivity of lung adenocarcinoma via regulating miR-497-5p/SMAD3. (PMID:36861928)
• Small peptide LINC00511-133aa encoded by LINC00511 regulates breast cancer cell invasion and stemness through the Wnt/beta-catenin pathway. (PMID:37068562)
• Comprehensive analysis of lncRNA-mRNA co-expression networks in HPV-driven cervical cancer reveals the pivotal function of LINC00511-PGK1 in tumorigenesis. (PMID:37099974)
• linc00511 Knockdown Inhibits Lung Cancer Progression by Regulating miR-16-5p/MMP11. (PMID:37602450)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.